First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer

A Phase I Study of the Chinese Herbal Medicine PHY906 as a Modulator of Irinotecan-based Chemotherapy in Patients with Advanced Colorectal Cancer

(2011) Shivaani Kummar et al.   Clinical Colorectal Cancer

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group

(2011) Uwe Pelzer et al.   EUROPEAN JOURNAL OF CANCER

De l’eau au moulin de thérapies ciblant l’interleukine-6 dans les tumeurs épithéliales

(2011) Angélique Gougelet et al.   M S-MEDECINE SCIENCES

Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS)

(2010) Wei Zhang et al.   JOURNAL OF CHROMATOGRAPHY A

Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies

(2010) M. Wasif Saif et al.   PHYTOMEDICINE

Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

(2009) David Cunningham et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of a Novel Capecitabine Schedule Based on the Norton-Simon Mathematical Model in Patients With Metastatic Breast Cancer

(2008) Tiffany A. Traina et al.   JOURNAL OF CLINICAL ONCOLOGY